Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor- (TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy

Lu Yu, Lichuang Men, Zongru Li, Xiaojun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 6358.

https://doi.org/10.1182/blood-2023-188406

Published: 2023

Journal Articles

Nbeal2 interacts with Dock7, Sec16a, and Vac14

Louisa Mayer, Maria Jasztal, Mercedes Pardo, Salvadora Aguera de Haro, Janine Collins, Tadbir K. Bariana, Peter A. Smethurst, Luigi Grassi, Romina Petersen, Paquita Nurden, Rémi Favier, Lu Yu, Stuart Meacham, William J. Astle, Jyoti Choudhary, Wyatt W. Yue, Willem H. Ouwehand, Jose A. Guerrero

Blood (2018) 131 (9): 1000–1011.

https://doi.org/10.1182/blood-2017-08-800359

Published: 2018

Includes: Supplemental data

Journal Articles

Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors

Qian Jiang, MD, Lu Yu, MD, Ya-Zhen Qin, Yue-Yun Lai, Xiao-Jun Huang, MD

Blood (2017) 130 (Supplement 1): 2876.

https://doi.org/10.1182/blood.V130.Suppl_1.2876.2876

Published: 2017

Journal Articles

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Lu Yu, MD, Qian Jiang, MD

Blood (2017) 130 (Supplement 1): 1605.

https://doi.org/10.1182/blood.V130.Suppl_1.1605.1605

Published: 2017

Journal Articles

Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy

Qian Jiang, MD, Xiao-Jun Huang, Lu Yu, Robert Peter Gale, MD PhD DSc

Blood (2016) 128 (22): 1927.

https://doi.org/10.1182/blood.V128.22.1927.1927

Published: 2016

Journal Articles

Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia

Qian Jiang, MD, Lu Yu, Robert Peter Gale, MD PhD DSc

Blood (2016) 128 (22): 3092.

https://doi.org/10.1182/blood.V128.22.3092.3092

Published: 2016

NARROW

Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor- (TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy

Nbeal2 interacts with Dock7, Sec16a, and Vac14

Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy

Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor- (TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy

Nbeal2 interacts with Dock7, Sec16a, and Vac14

Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy

Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only